Gilles Favre

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Living Beings

Physiology

Disorders

Adenocarcinoma

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Massabeau Carole; Rouquette Isabelle; Lauwers-Cances Valérie; Mazières Julien; Bachaud Jean-Marc; Armand Jean-Pierre; Delisle Marie-Bernadette; Favre Gilles; Toulas Christine; Cohen-Jonathan-Moyal Elizabeth
Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.
Bousquet Emilie; Mazières Julien; Privat Maud; Rizzati Virginie; Casanova Anne; Ledoux Adeline; Mery Eliane; Couderc Bettina; Favre Gilles; Pradines Anne
Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.
Skuli Nicolas; Monferran Sylvie; Delmas Caroline; Favre Gilles; Bonnet Jacques; Toulas Christine; Cohen-Jonathan Moyal Elizabeth
Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Gilles Favre (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Massabeau Carole; Rouquette Isabelle; Lauwers-Cances Valérie; Mazières Julien; Bachaud Jean-Marc; Armand Jean-Pierre; Delisle Marie-Bernadette; Favre Gilles; Toulas Christine; Cohen-Jonathan-Moyal Elizabeth
Basic fibroblast growth factor-2/beta3 integrin expression profile: signature of local progression after chemoradiotherapy for patients with locally advanced non-small-cell lung cancer.
International journal of radiation oncology, biology, physics 2009;75(3):696-702.
2009: Bousquet Emilie; Mazières Julien; Privat Maud; Rizzati Virginie; Casanova Anne; Ledoux Adeline; Mery Eliane; Couderc Bettina; Favre Gilles; Pradines Anne
Loss of RhoB expression promotes migration and invasion of human bronchial cells via activation of AKT1.
Cancer research 2009;69(15):6092-9.
2009: Skuli Nicolas; Monferran Sylvie; Delmas Caroline; Favre Gilles; Bonnet Jacques; Toulas Christine; Cohen-Jonathan Moyal Elizabeth
Alphavbeta3/alphavbeta5 integrins-FAK-RhoB: a novel pathway for hypoxia regulation in glioblastoma.
Cancer research 2009;69(8):3308-16.
2008: Tillement Vanessa; Lajoie-Mazenc Isabelle; Casanova Anne; Froment Carine; Penary Marie; Tovar Daniel; Marquez Rudolfo; Monsarrat Bernard; Favre Gilles; Pradines Anne
Phosphorylation of RhoB by CK1 impedes actin stress fiber organization and epidermal growth factor receptor stabilization.
Experimental cell research 2008;314(15):2811-21.
2008: Monferran Sylvie; Skuli Nicolas; Delmas Caroline; Favre Gilles; Bonnet Jacques; Cohen-Jonathan-Moyal Elizabeth; Toulas Christine
Alphavbeta3 and alphavbeta5 integrins control glioma cell response to ionising radiation through ILK and RhoB.
International journal of cancer. Journal international du cancer 2008;123(2):357-64.
2008: Lajoie-Mazenc Isabelle; Tovar Daniel; Penary Marie; Lortal Barbara; Allart Sophie; Favard Cyril; Brihoum Meryem; Pradines Anne; Favre Gilles
MAP1A light chain-2 interacts with GTP-RhoB to control epidermal growth factor (EGF)-dependent EGF receptor signaling.
The Journal of biological chemistry 2008;283(7):4155-64.
2008: Goffinet Marine; Chinestra Patrick; Lajoie-Mazenc Isabelle; Medale-Giamarchi Claire; Favre Gilles; Faye Jean-Charles
Identification of a GTP-bound Rho specific scFv molecular sensor by phage display selection.
BMC biotechnology 2008;8():34.
2007: Sarrabayrouse Guillaume; Synaeve Cindy; Leveque Kevin; Favre Gilles; Tilkin-Mariamé Anne-Françoise
Statins stimulate in vitro membrane FasL expression and lymphocyte apoptosis through RhoA/ROCK pathway in murine melanoma cells.
Neoplasia (New York, N.Y.) 2007;9(12):1078-90.
2007: Mazières Julien; Tovar Daniel; He Biao; Nieto-Acosta Jacobo; Marty-Detraves Claire; Clanet Carine; Pradines Anne; Jablons David; Favre Gilles
Epigenetic regulation of RhoB loss of expression in lung cancer.
BMC cancer 2007;7():220.
2006: Paillasse Michaël R; Deraeve Céline; de Medina Philippe; Mhamdi Loubna; Favre Gilles; Poirot Marc; Silvente-Poirot Sandrine
Insights into the cholecystokinin 2 receptor binding site and processes of activation.
Molecular pharmacology 2006;70(6):1935-45.
2006: de Medina Philippe; Boubekeur Nadia; Balaguer Patrick; Favre Gilles; Silvente-Poirot Sandrine; Poirot Marc
The prototypical inhibitor of cholesterol esterification, Sah 58-035 [3-[decyldimethylsilyl]-n-[2-(4-methylphenyl)-1-phenylethyl]propanamide], is an agonist of estrogen receptors.
The Journal of pharmacology and experimental therapeutics 2006;319(1):139-49.
2006: Skuli Nicolas; Monferran Sylvie; Delmas Caroline; Lajoie-Mazenc Isabelle; Favre Gilles; Toulas Christine; Cohen-Jonathan-Moyal Elizabeth
Activation of RhoB by hypoxia controls hypoxia-inducible factor-1alpha stabilization through glycogen synthase kinase-3 in U87 glioblastoma cells.
Cancer research 2006;66(1):482-9.
2006: Couderc Bettina; Penary Marie; Tohfe Mustapha; Pradines Anne; Casteignau Antoine; Berg Danièle; Favre Gilles
Reversible inactivation of the transcriptional function of P53 protein by farnesylation.
BMC biotechnology 2006;6():26.
2005: Canguilhem Bruno; Pradines Anne; Baudouin Caroline; Boby Céline; Lajoie-Mazenc Isabelle; Charveron Marie; Favre Gilles
RhoB protects human keratinocytes from UVB-induced apoptosis through epidermal growth factor receptor signaling.
The Journal of biological chemistry 2005;280(52):43257-63.
2005: Cormary Carine; Hiver Elsa; Mariamé Bernard; Favre Gilles; Tilkin-Mariamé Anne-Françoise
Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity.
Cancer gene therapy 2005;12(12):963-72.
2005: Tilkin-Mariamé A-F; Cormary C; Ferro N; Sarrabayrouse G; Lajoie-Mazenc I; Faye J-C; Favre G
Geranylgeranyl transferase inhibition stimulates anti-melanoma immune response through MHC Class I and costimulatory molecule expression.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005;19(11):1513-5.
2005: Boijoux O; Boutonnet C; Giamarchi C; Favre G; Vagner S; Faye J C
Chemical-based translational induction of luciferase expression: an efficient tool for in vivo screening of protein farnesylation inhibitors.
Molecular pharmacology 2005;67(6):1829-33.
2005: Milia J; Teyssier F; Dalenc F; Ader I; Delmas C; Pradines A; Lajoie-Mazenc I; Baron R; Bonnet J; Cohen-Jonathan E; Favre G; Toulas C
Farnesylated RhoB inhibits radiation-induced mitotic cell death and controls radiation-induced centrosome overduplication.
Cell death and differentiation 2005;12(5):492-501.
2005: Mazières Julien; Tillement Vanessa; Allal Cuider; Clanet Carine; Bobin Lisbeth; Chen Zhi; Sebti Said M; Favre Gilles; Pradines Anne
Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cells.
Experimental cell research 2005;304(2):354-64.
2005: Cestac Ph; Doisneau-Sixou S; Favre G
[Development of farsenyl transferase inhibitors as anticancer agents]
Annales pharmaceutiques françaises 2005;63(1):76-84.
2005: Dalenc Florence; Giamarchi Claire; Petit Mélissa; Poirot Marc; Favre Gilles; Faye Jean-Charles
Farnesyl-transferase inhibitor R115,777 enhances tamoxifen inhibition of MCF-7 cell growth through estrogen receptor dependent and independent pathways.
Breast cancer research : BCR 2005;7(6):R1159-67.
2005: Cestac Philippe; Sarrabayrouse Guillaume; Médale-Giamarchi Claire; Rochaix Philippe; Balaguer Patrick; Favre Gilles; Faye Jean-Charles; Doisneau-Sixou Sophie
Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.
Breast cancer research : BCR 2005;7(1):R60-70.
2004: de Médina Philippe; Favre Gilles; Poirot Marc
Multiple targeting by the antitumor drug tamoxifen: a structure-activity study.
Current medicinal chemistry. Anti-cancer agents 2004;4(6):491-508.
2004: Kedjouar Blandine; de Médina Philippe; Oulad-Abdelghani Mustapha; Payré Bruno; Silvente-Poirot Sandrine; Favre Gilles; Faye Jean-Charles; Poirot Marc
Molecular characterization of the microsomal tamoxifen binding site.
The Journal of biological chemistry 2004;279(32):34048-61.
2004: Douin Victorine; Bornes Stephanie; Creancier Laurent; Rochaix Philippe; Favre Gilles; Prats Anne-Catherine; Couderc Bettina
Use and comparison of different internal ribosomal entry sites (IRES) in tricistronic retroviral vectors.
BMC biotechnology 2004;4():16.
2004: Boutonnet Christel; Boijoux Olivier; Bernat Sandra; Kharrat Abdelhakkim; Favre Gilles; Faye Jean-Charles; Vagner Stéphan
Pharmacological-based translational induction of transgene expression in mammalian cells.
EMBO reports 2004;5(7):721-7.
2004: Cormary Carine; Gonzalez Ricardo; Faye Jean-Charles; Favre Gilles; Tilkin-Mariamé Anne-Françoise
Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules.
Cancer gene therapy 2004;11(7):497-507.
2004: Mazieres Julien; Antonia Teresita; Daste Ghislaine; Muro-Cacho Carlos; Berchery Delphine; Tillement Vanessa; Pradines Anne; Sebti Said; Favre Gilles
Loss of RhoB expression in human lung cancer progression.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(8):2742-50.
2004: Mazieres Julien; Pradines Anne; Favre Gilles
Perspectives on farnesyl transferase inhibitors in cancer therapy.
Cancer letters 2004;206(2):159-67.
2004: Peron Jean-Marie; Couderc Bettina; Rochaix Philippe; Douin-Echinard Victorine; Asnacios Amani; Souque Anny; Voigt Jean-Jacques; Buscail Louis; Vinel Jean-Pierre; Favre Gilles
Treatment of murine hepatocellular carcinoma using genetically modified cells to express interleukin-12.
Journal of gastroenterology and hepatology 2004;19(4):388-96.
2004: de Medina Philippe; Payré Bruno L; Bernad José; Bosser Isabelle; Pipy Bernard; Silvente-Poirot Sandrine; Favre Gilles; Faye Jean-Charles; Poirot Marc
Tamoxifen is a potent inhibitor of cholesterol esterification and prevents the formation of foam cells.
The Journal of pharmacology and experimental therapeutics 2004;308(3):1165-73.
2003: Delmas Caroline; End Dave; Rochaix Philippe; Favre Gilles; Toulas Christine; Cohen-Jonathan Elizabeth
The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(16 Pt 1):6062-8.
2003: Ader Isabelle; Delmas Caroline; Bonnet Jacques; Rochaix Philippe; Favre Gilles; Toulas Christine; Cohen-Jonathan-Moyal Elizabeth
Inhibition of Rho pathways induces radiosensitization and oxygenation in human glioblastoma xenografts.
Oncogene 2003;22(55):8861-9.
2003: Doisneau-Sixou Sophie F; Cestac Philippe; Faye Jean-Charles; Favre Gilles; Sutherland Robert L
Additive effects of tamoxifen and the farnesyl transferase inhibitor FTI-277 on inhibition of MCF-7 breast cancer cell-cycle progression.
International journal of cancer. Journal international du cancer 2003;106(5):789-98.
2003: Tovar Daniel; Faye Jean-Charles; Favre Gilles
Cloning of the human RHOB gene promoter: characterization of a VNTR sequence that affects transcriptional activity.
Genomics 2003;81(5):525-30.
2003: Douin-Echinard Victorine; Péron Jean-Marie; Lauwers-Cancès Valérie; Favre Gilles; Couderc Bettina
Involvement of CD70 and CD80 intracytoplasmic domains in the co-stimulatory signal required to provide an antitumor immune response.
International immunology 2003;15(3):359-72.
2003: Doisneau-Sixou Sophie F; Cestac Philippe; Chouini Sarah; Carroll Jason S; Hamilton Andrew D; Sebti Said M; Poirot Marc; Balaguer Patrick; Faye Jean-Charles; Sutherland Robert L; Favre Gilles
Contrasting effects of prenyltransferase inhibitors on estrogen-dependent cell cycle progression and estrogen receptor-mediated transcriptional activity in MCF-7 cells.
Endocrinology 2003;144(3):989-98.
2003: Mazières Julien; Pradines Anne; Favre Gilles
[Farnesyl transferase inhibitors: one target may be found in another]
Médecine sciences : M/S 2003;19(2):211-6.
2002: Allal Cuider; Pradines Anne; Hamilton Andrew D; Sebti Said M; Favre Gilles
Farnesylated RhoB prevents cell cycle arrest and actin cytoskeleton disruption caused by the geranylgeranyltransferase I inhibitor GGTI-298.
Cell cycle (Georgetown, Tex.) 2002;1(6):430-7.
2002: Ader Isabelle; Muller Catherine; Bonnet Jacques; Favre Gilles; Cohen-Jonathan Elizabeth; Salles Bernard; Toulas Christine
The radioprotective effect of the 24 kDa FGF-2 isoform in HeLa cells is related to an increased expression and activity of the DNA dependent protein kinase (DNA-PK) catalytic subunit.
Oncogene 2002;21(42):6471-9.
2002: Ader Isabelle; Toulas Christine; Dalenc Florence; Delmas Caroline; Bonnet Jacques; Cohen-Jonathan Elizabeth; Favre Gilles
RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.
Oncogene 2002;21(39):5998-6006.
2002: Dalenc Florence; Drouet Jerome; Ader Isabelle; Delmas Caroline; Rochaix Philippe; Favre Gilles; Cohen-Jonathan Elizabeth; Toulas Christine
Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells.
International journal of cancer. Journal international du cancer 2002;100(6):662-8.
2002: Delmas Caroline; Heliez Christophe; Cohen-Jonathan Elizabeth; End Dave; Bonnet Jacques; Favre Gilles; Toulas Christine
Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.
International journal of cancer. Journal international du cancer 2002;100(1):43-8.
2002: Grangeon Cendrine; Cormary Carine; Douin-Echinard Vickorine; Favre Gilles; Couderc Bettina; Tilkin-Mariamé Anne-Françoise
In vivo induction of antitumor immunity and protection against tumor growth by injection of CD154-expressing tumor cells.
Cancer gene therapy 2002;9(3):282-8.
2001: Prevost G P; Pradines A; Brezak M C; Lonchampt M O; Viossat I; Ader I; Toulas C; Kasprzyk P; Gordon T; Favre G; Morgan B
Inhibition of human tumor cell growth in vivo by an orally bioavailable inhibitor of human farnesyltransferase, BIM-46228.
International journal of cancer. Journal international du cancer 2001;91(5):718-22.
2000: Douin-Echinard V; Bornes S; Rochaix P; Tilkin A F; Peron J M; Bonnet J; Favre G; Couderc B
The expression of CD70 and CD80 by gene-modified tumor cells induces an antitumor response depending on the MHC status.
Cancer gene therapy 2000;7(12):1543-56.
2000: Baron R; Fourcade E; Lajoie-Mazenc I; Allal C; Couderc B; Barbaras R; Favre G; Faye J C; Pradines A
RhoB prenylation is driven by the three carboxyl-terminal amino acids of the protein: evidenced in vivo by an anti-farnesyl cysteine antibody.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(21):11626-31.
2000: Allal C; Favre G; Couderc B; Salicio S; Sixou S; Hamilton A D; Sebti S M; Lajoie-Mazenc I; Pradines A
RhoA prenylation is required for promotion of cell growth and transformation and cytoskeleton organization but not for induction of serum response element transcription.
The Journal of biological chemistry 2000;275(40):31001-8.
2000: Chen Z; Sun J; Pradines A; Favre G; Adnane J; Sebti S M
Both farnesylated and geranylgeranylated RhoB inhibit malignant transformation and suppress human tumor growth in nude mice.
The Journal of biological chemistry 2000;275(24):17974-8.
1999: Cohen-Jonathan E; Toulas C; Ader I; Monteil S; Allal C; Bonnet J; Hamilton A D; Sebti S M; Daly-Schveitzer N; Favre G
The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.
Radiation research 1999;152(4):404-11.
1999: Prevost G P; Pradines A; Viossat I; Brezak M C; Miquel K; Lonchampt M O; Kasprzyk P; Favre G; Pignol B; Le Breton C; Dong J; Morgan B
Inhibition of human tumor cell growth in vitro and in vivo by a specific inhibitor of human farnesyltransferase: BIM-46068.
International journal of cancer. Journal international du cancer 1999;83(2):283-7.
1999: Asslan R; Pradines A; Pratx C; Allal C; Favre G; Le Gaillard F
Epidermal growth factor stimulates 3-hydroxy-3-methylglutaryl-coenzyme A reductase expression via the ErbB-2 pathway in human breast adenocarcinoma cells.
Biochemical and biophysical research communications 1999;260(3):699-706.
1998: Miquel K; Pradines A; Tercé F; Selmi S; Favre G
Competitive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells.
The Journal of biological chemistry 1998;273(40):26179-86.
1998: Allal C; Sixou S; Kravtzoff R; Soulet N; Soula G; Favre G
SupraMolecular BioVectors (SMBV) improve antisense inhibition of erbB-2 expression.
British journal of cancer 1998;77(9):1448-53.
1998: Couderc B; Zitvogel L; Douin-Echinard V; Djennane L; Tahara H; Favre G; Lotze M T; Robbins P D
Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells.
Cancer gene therapy 1998;5(3):163-75.
1998: Asslan R; Pradines A; Favre G; Le Gaillard F
Tyrosine kinase-dependent modulation of 3-hydroxy-3-methylglutaryl-CoA reductase in human breast adenocarcinoma SKBR-3 cells.
The Biochemical journal 1998;330 ( Pt 1)():241-6.
1998: Douin-Echinard V; Robbins P D; Lotze M T; Favre G; Couderc B
Enhancement of anti-tumor immunity by injection of fibroblasts genetically engineered to produce IL-12 and to express CD70.
Advances in experimental medicine and biology 1998;451():353-7.
1997: Miquel K; Pradines A; Sun J; Qian Y; Hamilton A D; Sebti S M; Favre G
GGTI-298 induces G0-G1 block and apoptosis whereas FTI-277 causes G2-M enrichment in A549 cells.
Cancer research 1997;57(10):1846-50.
1997: Cohen-Jonathan E; Toulas C; Monteil S; Couderc B; Maret A; Bard J J; Prats H; Daly-Schveitzer N; Favre G
Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells.
Cancer research 1997;57(7):1364-70.
1997: Cohen-Jonathan E; Toulas C; Rochaix P; Bachaud J M; Daly-Schveitzer N; Favre G
Preferential cytoplasmic localization of p34cdc2 in recurrent human squamous cell carcinoma after radiotherapy.
Radiation research 1997;147(3):277-83.
1997: Berton M; Sixou S; Kravtzoff R; Dartigues C; Imbertie L; Allal C; Favre G
Improved oligonucleotide uptake and stability by a new drug carrier, the SupraMolecular Bio Vector (SMBV).
Biochimica et biophysica acta 1997;1355(1):7-19.
1996: Miquel K; Pradines A; Favre G
Farnesol and geranylgeraniol induce actin cytoskeleton disorganization and apoptosis in A549 lung adenocarcinoma cells.
Biochemical and biophysical research communications 1996;225(3):869-76.
1996: Toulas C; Mihura J; de Balincourt C; Marques B; Marek E; Soula G; Roche H; Favre G
Potential prognostic value in human breast cancer of cytosolic Nme1 protein detection using an original hen specific antibody.
British journal of cancer 1996;73(5):630-5.
1996: Jasanada F; Urizzi P; Souchard J P; Le Gaillard F; Favre G; Nepveu F
Indium-111 labeling of low density lipoproteins with the DTPA-bis(stearylamide): evaluation as a potential radiopharmaceutical for tumor localization.
Bioconjugate chemistry 1996;7(1):72-81.
1996: Gueddari N; Favre G; Marmouget C; Soula G; Le Gaillard F
Involvement of tyrosine kinase activity in the low-density lipoprotein receptor expression in human lung adenocarcinoma cell line A549.
Biochimie 1996;78(10):874-81.
1995: Tazi K A; Bonnafous M; Favre G; Soula G; Le Gaillard F
Involvement of the Ca(2+)-dependent phosphorylation of a 20 kDa protein in the proliferative effect of high-density lipoproteins (subclass 3) on the adenocarcinoma cell line A549.
The Biochemical journal 1995;307 ( Pt 2)():557-61.
1993: Bennis F; Favre G; Le Gaillard F; Soula G
Importance of mevalonate-derived products in the control of HMG-CoA reductase activity and growth of human lung adenocarcinoma cell line A549.
International journal of cancer. Journal international du cancer 1993;55(4):640-5.
1993: Samadi-Baboli M; Favre G; Canal P; Soula G
Low density lipoprotein for cytotoxic drug targeting: improved activity of elliptinium derivative against B16 melanoma in mice.
British journal of cancer 1993;68(2):319-26.
1993: Favre G; Tazi K A; Le Gaillard F; Bennis F; Hachem H; Soula G
High density lipoprotein3 binding sites are related to DNA biosynthesis in the adenocarcinoma cell line A549.
Journal of lipid research 1993;34(7):1093-106.
1993: Gueddari N; Favre G; Hachem H; Marek E; Le Gaillard F; Soula G
Evidence for up-regulated low density lipoprotein receptor in human lung adenocarcinoma cell line A549.
Biochimie 1993;75(9):811-9.
1991: Hachem H; Saile R; Favre G; Bosco R; Raynal G; Fruchart J C; Soula G
A sensitive immunochemiluminescence assay for human serum amyloid A protein.
Clinical biochemistry 1991;24(2):143-7.
1990: Samadi-Baboli M; Favre G; Bernadou J; Berg D; Soula G
Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug--LDL complex via the LDL receptor pathway in vitro.
Biochemical pharmacology 1990;40(2):203-12.
1990: Guérin J L; Favre G; Raynal G; Soula G
[Determination of cerebrospinal fluid proteins using the Cobas Fara centrifugal analyser. Adaptation of the turbidimetric technic to benzethonium chloride]
Annales de biologie clinique 1990;48(3):167-70.
1989: Favre G; Blancy E; Tournier J F; Soula G
Proliferative effect of high density lipoprotein (HDL) and HDL fractions (HDL1,2, HDL3) on virus transformed lymphoblastoid cells.
Biochimica et biophysica acta 1989;1013(2):118-24.
1989: Samadi-Baboli M; Favre G; Blancy E; Soula G
Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro.
European journal of cancer & clinical oncology 1989;25(2):233-41.
1989: Samadi-Baboli M; Favre G; Soula G
[Vectorization of antineoplastic drugs by low density lipoproteins: incorporation of acyl celiptium and metabolism of complexes in the cellular receptor of human fibroblasts]
Bulletin du cancer 1989;76(8):853-7.
1988: Hachem H; Favre G; Soula G
Evidence for qualitative abnormalities in high-density lipoproteins from myeloma patients: the presence of amyloid A protein could explain HDL modifications.
Biochimica et biophysica acta 1988;963(2):271-7.
1987: Hachem H; Favre G; Ghalim N; Puchois P; Fruchart J C; Soula G
Quantitative abnormalities of lipoprotein particles in multiple myeloma.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1987;25(10):675-9.
1986: Hachem H; Favre G; Raynal G; Blavy G; Canal P; Soula G
Serum apolipoproteins A-I, A-II and B in hepatic metastases. Comparison with other liver diseases: hepatomas and cirrhosis.
Journal of clinical chemistry and clinical biochemistry. Zeitschrift für klinische Chemie und klinische Biochemie 1986;24(3):161-6.
1985: Hachem H; Raynal G; Favre G; Hamza M; Canal P; Soula G
[Determination of serum apolipoproteins A1 and B by immunoturbidimetry using the Cobas-Bio centrifugal analyzer. Influence of hyperlipemia]
Annales de biologie clinique 1985;43(6):885-90.
1984: Favre G; Le Gaillard F; Mattret-Turrion M H; Dumur V; Dautrevaux M
Physico-chemical properties and evidence for electrophoretic variants of rat transcortin.
Biochimie 1984;66(5):361-9.
1983: Le Gaillard F; Azam H; Favre G; Dautrevaux M
Reversible dissociation of cortisol-transcortin complex by sodium para-chloromercuribenzoate.
Biochimica et biophysica acta 1983;749(3):289-95.
1983: Hachem H; Favre G; Raynal G; Soula G
[Plasma lipoproteins and multiple myeloma. Variations of lipid constituents of HDL and apolipoproteins A1 and B]
Annales de biologie clinique 1983;41(3):181-5.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Gilles Favre

Research Profile (preview)

Chemicals & Drugs

Anatomy

Living Beings

Physiology

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Gilles Favre (preview)

All Publications